IGHG Recommendations for Coronary Artery Disease Surveillance Among Childhood, Adolescent and Young Adult Cancer Survivors

Join Dr Elvira C van Dalen (Princess Máxima Center for Pediatric Oncology, NL), Dr Annelies Mavinkurve-Groothuis (Princess Máxima Center for Pediatric Oncology, NL), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) in this upcoming webinar to discuss recommendations from the International Late Effects of Childhood Cancer Guideline Harmonisation Group (IGHG).

This session will explore critical guidelines for monitoring coronary artery disease in survivors of childhood, adolescent and young adult cancers. Experts will share evidence-based recommendations aimed at improving long-term cardiovascular health outcomes in this vulnerable population. The webinar will provide valuable insights for healthcare professionals involved in survivorship care, with a focus on harmonised global approaches to early detection and prevention of coronary artery disease.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.